These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 39307151

  • 1. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

  • 3. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 4. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 5. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW, TOPIC Study Group.
    Lancet Neurol; 2014 Oct 20; 13(10):977-86. PubMed ID: 25192851
    [Abstract] [Full Text] [Related]

  • 6. Teriflunomide for multiple sclerosis.
    He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.
    Cochrane Database Syst Rev; 2016 Mar 22; 3(3):CD009882. PubMed ID: 27003123
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A, Tolebrutinib Phase 2b Study Group.
    Lancet Neurol; 2021 Sep 22; 20(9):729-738. PubMed ID: 34418400
    [Abstract] [Full Text] [Related]

  • 8. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdová EK, Hennessy B, Hohlfeld R, Lublin F, Montalban X, Pozzilli C, Scherz T, D'Ambrosio D, Linscheid P, Vaclavkova A, Pirozek-Lawniczek M, Kracker H, Sprenger T.
    JAMA Neurol; 2021 May 01; 78(5):558-567. PubMed ID: 33779698
    [Abstract] [Full Text] [Related]

  • 9. Teriflunomide for multiple sclerosis.
    He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.
    Cochrane Database Syst Rev; 2012 Dec 12; 12():CD009882. PubMed ID: 23235682
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Williams MJ, Amezcua L, Cohan SL, Cohen JA, Delgado SR, Hua LH, Lucassen EB, Piccolo RS, Koulouris CR, Stankiewicz J.
    Neurology; 2024 Aug 13; 103(3):e209610. PubMed ID: 39018512
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
    Jones RR, Turkoz I, Ait-Tihyaty M, DiBernardo A, Houtchens MK, Havrdová EK.
    J Womens Health (Larchmt); 2024 Apr 13; 33(4):480-490. PubMed ID: 38301149
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA, Comi G, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Huang V, Kappos L, RADIANCE Trial Investigators.
    Lancet Neurol; 2019 Nov 13; 18(11):1021-1033. PubMed ID: 31492652
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
    Qiu W, Huang DH, Hou SF, Zhang MN, Jin T, Dong HQ, Peng H, Zhang CD, Zhao G, Huang YN, Zhou D, Wu WP, Wang BJ, Li JM, Zhang XH, Cheng Y, Li HF, Li L, Lu CZ, Zhang X, Bu BT, Dong WL, Fan DS, Hu XQ, Xu XH, TOWER Trial Chinese Group.
    Chin Med J (Engl); 2018 Dec 05; 131(23):2776-2784. PubMed ID: 30511679
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G, Kappos L, Selmaj KW, Bar-Or A, Arnold DL, Steinman L, Hartung HP, Montalban X, Kubala Havrdová E, Cree BAC, Sheffield JK, Minton N, Raghupathi K, Ding N, Cohen JA, SUNBEAM Study Investigators.
    Lancet Neurol; 2019 Nov 05; 18(11):1009-1020. PubMed ID: 31492651
    [Abstract] [Full Text] [Related]

  • 15. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC, ULTIMATE I and ULTIMATE II Investigators.
    N Engl J Med; 2022 Aug 25; 387(8):704-714. PubMed ID: 36001711
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS.
    Mult Scler; 2024 Apr 25; 30(4-5):558-570. PubMed ID: 38436271
    [Abstract] [Full Text] [Related]

  • 17. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M.
    Mult Scler; 2024 Jun 25; 30(7):833-842. PubMed ID: 38619037
    [Abstract] [Full Text] [Related]

  • 18. Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Arnold DL, Elliott C, Martin EC, Hyvert Y, Tomic D, Montalban X.
    Neurology; 2024 Mar 12; 102(5):e208058. PubMed ID: 38335474
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 12; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
    Miller AE, Xu X, Macdonell R, Vucic S, Truffinet P, Benamor M, Thangavelu K, Freedman MS.
    J Clin Neurosci; 2019 Jan 12; 59():229-231. PubMed ID: 30348586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.